New York State Common Retirement Fund lifted its stake in C.R. Bard, Inc. (NYSE:BCR) by 2.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 162,600 shares of the medical instruments supplier’s stock after purchasing an additional 3,500 shares during the quarter. New York State Common Retirement Fund owned 0.22% of C.R. Bard worth $52,113,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors and hedge funds also recently bought and sold shares of the company. Mitsubishi UFJ Securities Holdings Co. Ltd. raised its position in shares of C.R. Bard by 70.4% in the 2nd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 460 shares of the medical instruments supplier’s stock worth $145,000 after purchasing an additional 190 shares during the last quarter. Parallel Advisors LLC raised its position in C.R. Bard by 2.8% in the 2nd quarter. Parallel Advisors LLC now owns 513 shares of the medical instruments supplier’s stock worth $164,000 after buying an additional 14 shares during the last quarter. Captrust Financial Advisors purchased a new position in C.R. Bard in the 2nd quarter worth about $192,000. Choate Investment Advisors purchased a new position in C.R. Bard in the 2nd quarter worth about $201,000. Finally, Highstreet Asset Management Inc. purchased a new position in C.R. Bard in the 2nd quarter worth about $209,000. 79.21% of the stock is owned by hedge funds and other institutional investors.
A number of equities analysts have weighed in on the company. ValuEngine lowered C.R. Bard from a “buy” rating to a “hold” rating in a research report on Friday, December 1st. Barclays boosted their target price on C.R. Bard from $245.00 to $337.00 and gave the stock an “equal weight” rating in a research report on Monday, November 6th. Cowen reissued a “hold” rating and issued a $317.00 target price on shares of C.R. Bard in a research report on Friday, November 3rd. Needham & Company LLC reissued a “hold” rating on shares of C.R. Bard in a research report on Thursday, October 26th. Finally, Jefferies Group reissued a “hold” rating and issued a $317.00 target price on shares of C.R. Bard in a research report on Thursday, September 14th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and one has given a strong buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $303.50.
C.R. Bard (NYSE:BCR) last released its quarterly earnings results on Wednesday, October 25th. The medical instruments supplier reported $3.02 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.96 by $0.06. The business had revenue of $989.80 million during the quarter, compared to the consensus estimate of $990.64 million. C.R. Bard had a return on equity of 48.28% and a net margin of 14.75%. The business’s quarterly revenue was up 5.1% compared to the same quarter last year. During the same period in the previous year, the company posted $2.64 EPS. equities research analysts anticipate that C.R. Bard, Inc. will post 11.89 earnings per share for the current year.
The company also recently declared a quarterly dividend, which will be paid on Friday, December 29th. Shareholders of record on Friday, December 8th will be paid a dividend of $0.26 per share. The ex-dividend date is Thursday, December 7th. This represents a $1.04 dividend on an annualized basis and a dividend yield of 0.31%. C.R. Bard’s dividend payout ratio is currently 13.70%.
In other C.R. Bard news, insider Timothy P. Collins sold 8,388 shares of the business’s stock in a transaction dated Monday, October 9th. The stock was sold at an average price of $322.00, for a total transaction of $2,700,936.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Timothy P. Collins sold 55,818 shares of the business’s stock in a transaction that occurred on Thursday, October 12th. The shares were sold at an average price of $322.03, for a total value of $17,975,070.54. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 191,593 shares of company stock valued at $62,655,513. Corporate insiders own 0.80% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “C.R. Bard, Inc. (BCR) Stake Boosted by New York State Common Retirement Fund” was first published by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece of content on another website, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.com-unik.info/2017/12/06/c-r-bard-inc-bcr-stake-boosted-by-new-york-state-common-retirement-fund.html.
C.R. Bard Company Profile
C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.
Want to see what other hedge funds are holding BCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for C.R. Bard, Inc. (NYSE:BCR).
What are top analysts saying about C.R. Bard Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for C.R. Bard Inc. and related companies.